Scienture provides update on commercial launch of REZENOPY

Scienture (SCNX) provided an update on the commercial launch of REZENOPY. As previously disclosed, Scienture, a wholly owned subsidiary of Scienture Holdings, entered into a definitive agreement with Summit Biosciences in March 2025, for the exclusive U.S. commercialization rights to REZENOPY Nasal Spray 10 mg, which received FDA approval on April 19, 2024. “REZENOPY represents a significant advancement in overdose response as the highest-strength naloxone available on the market at 10 mg. It is specifically designed for patients who often require multiple doses of lower-strength naloxone for stabilization in emergency situations,” commented Narasimhan Mani, President and co-CEO of Scienture. “By delivering a higher dose of naloxone, REZENOPY is intended to support opioid receptor antagonism and may help address overdose situations where multiple or potent opioids are involved.”